← Leaderboards
John H. Kempen
Johns Hopkins University
$14,361,889
Attributed
$14,960,851
Total exposure
8
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.5M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,631,179 · 7
FDA$329,672 · 1
By mechanism
R01$8,447,521 · 2
UG1$4,205,881 · 1
R21$986,779 · 2
R33$706,103 · 1
K23$455,400 · 1
R56$159,167 · 1
Top collaborators
- Gang Luo4 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Douglas A Jabs$24,554,490
- Janet T. Holbrook$51,624,279
- Mark J Shelhamer$2,482,209
- Meraf A Wolle$638,385
- Deborah K Armstrong$3,693,943
Others in their field
Top investigators on “Vision”
- Chanza Baytop · Westat, Inc.$271,217,917
- Edward W Maly · United Nations Children'S Fund$264,005,699
- Eric J Barron · Pennsylvania State Univ University Park$243,972,016
- Antonio J Busalacchi · University Of Maryland, College Park$243,972,016
- Valerie Koch · University Corporation For Atmospheric Res$243,972,016
- Everette D Joseph · Howard University$243,972,016
Research focus
VisionBlindnessAffectIncidenceInflammationAdrenal Cortex HormonesCostBaseSafetyReportingLifeUptakeUveitisCaringMalignant NeoplasmsDoseScleritisTherapeutic ImmunosuppressionInflammatoryImmunosuppressive AgentsCohortAlkylating AgentsCost EffectivenessCessation Of Life
Grant awards (29)
Long-term Follow-up of the Systemic Immunosuppressive Therapy for Eye Diseases Cohort$2,236,075
R01 · FY2025 · EY · contact PI
Overcome the barriers of vision care in Africa using smartphones$313,856
R33 · FY2025 · EY
Overcome the barriers of vision care in Africa using smartphones$392,247
R33 · FY2024 · EY
Fluorometholone as Adjunctive Therapy for Trachomatous Trichiasis Surgery$547,869
UG1 · FY2023 · EY · contact PI
Overcome the barriers of vision care in Africa using smartphones$245,074
R21 · FY2023 · EY
Fluorometholone as Adjunctive Therapy for Trachomatous Trichiasis Surgery$669,892
UG1 · FY2022 · EY · contact PI
Overcome the barriers of vision care in Africa using smartphones$246,748
R21 · FY2022 · EY
Fluorometholone as Adjunctive Therapy for Trachomatous Trichiasis Surgery$917,801
UG1 · FY2021 · EY · contact PI
Fluorometholone as Adjunctive Therapy for Trachomatous Trichiasis Surgery$1,071,471
UG1 · FY2020 · EY · contact PI
Fluorometholone as Adjunctive Therapy for Trachomatous Trichiasis Surgery$998,848
UG1 · FY2019 · EY · contact PI
Incidence of remission and of cataract in ocular inflammatory diseases$238,501
R21 · FY2018 · EY · contact PI
Incidence of remission and of cataract in ocular inflammatory diseases$29,155
R21 · FY2018 · EY · contact PI
Incidence of remission and of cataract in ocular inflammatory diseases$227,301
R21 · FY2017 · EY · contact PI
Complications of Immunosuppression for Eye Diseases$616,325
R01 · FY2014 · EY · contact PI
Complications of Immunosuppression for Eye Diseases$693,418
R01 · FY2013 · EY · contact PI
Phase 1 Iontophoretic Delivery of Dexamethasone for Tx of Anterior Scleritis$155,385
R01 · FY2013 · FD · contact PI
Complications of Immunosuppression for Eye Diseases$726,910
R01 · FY2012 · EY · contact PI
Complications of Immunosuppression for Eye Diseases$743,668
R01 · FY2011 · EY · contact PI
Phase 1 Iontophoretic Delivery of Dexamethasone for Tx of Anterior Scleritis$174,287
R01 · FY2011 · FD · contact PI
Complications of Immunosuppression for Eye Diseases$829,809
R01 · FY2010 · EY · contact PI
Complications of Immunosupression for Eye Diseases$159,167
R56 · FY2009 · EY · contact PI
Complications of Immunosupression for Eye Diseases$531,213
R01 · FY2007 · EY · contact PI
Complications of Immunosupression for Eye Diseases$618,704
R01 · FY2006 · EY · contact PI
Complications of Immunosupression for Eye Diseases$535,690
R01 · FY2005 · EY
Complications of Immunosupression for Eye Diseases$53,479
R01 · FY2005 · EY
Complications of Immunosupression for Eye Diseases$532,558
R01 · FY2004 · EY
QUALITY OF LIFE AND COST EFFECTIVENESS IN CMV RETINITIS$156,190
K23 · FY2002 · EY
QUALITY OF LIFE AND COST EFFECTIVENESS IN CMV RETINITIS$151,765
K23 · FY2001 · EY
QUALITY OF LIFE AND COST EFFECTIVENESS IN CMV RETINITIS$147,445
K23 · FY2000 · EY